{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:30:03Z","timestamp":1771299003709,"version":"3.50.1"},"reference-count":12,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,5,18]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Malignant neoplasms of salivary gland neoplasms are rare and often involve the parotid gland. The primary treatment of these malignancies is surgery with or without adjuvant therapy. Chemotherapy or systemic therapy is indicated in recurrent or metastatic disease where surgery or radiotherapy is not possible. Salivary gland carcinomas, which are human epidermal growth factor receptor 2 (HER2) positive, show an aggressive behaviour with a poor prognosis. Targeting the HER2 pathway with drugs designed to block this pathway is an interesting novel therapy to treat salivary gland carcinomas. We report a case of a patient with HER 2-overexpressing parotid gland adenocarcinoma with brain metastasis, who was managed with ado-trastuzumab emtansine (T-DM1): a monoclonal antibody-cytotoxic drug conjugate that combines trastuzumab with the microtubule inhibitor, emtansine. The patient showed excellent response to the therapy. This case highlights the role of systemic chemotherapy with T-DM1 in HER2 positive salivary gland tumours that could be considered a part of the treatment regimen.<\/jats:p>","DOI":"10.1136\/bcr-2021-248576","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T11:33:12Z","timestamp":1653996792000},"page":"e248576","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Role of ado-trastuzumab emtansine (T-DM1) in HER2 positive salivary gland tumour with brain metastasis"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct02675829","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3408-4508","authenticated-orcid":false,"given":"Nilesh","family":"Dhamne","sequence":"first","affiliation":[{"name":"Medical Oncology, Kolhapur Cancer Centre, Kolhapur, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3968-8354","authenticated-orcid":false,"given":"Venkata Pradeep Babu","family":"Koyyala","sequence":"additional","affiliation":[{"name":"Medical Oncology, Tezpur Cancer Centre, Assam Cancer Care Foundation, Tezpur, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snehal","family":"Chougule","sequence":"additional","affiliation":[{"name":"Neurology, Kolhapur Cancer Centre, Kolhapur, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suraj","family":"Pawar","sequence":"additional","affiliation":[{"name":"Surgical Oncology, Kolhapur Cancer Centre, Kolhapur, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"2025082802595984000_15.5.e248576.1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.bulcan.2018.04.004","article-title":"[WHO classification of head and neck tumours 2017: Main novelties and update of diagnostic methods]","volume":"105","author":"Sarradin","year":"2018","journal-title":"Bull Cancer"},{"key":"2025082802595984000_15.5.e248576.2","article-title":"Maintenance therapy with trastuzumab in HER2 positive metastatic parotid ductal adenocarcinoma","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Case Rep Oncol Med"},{"key":"2025082802595984000_15.5.e248576.3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000488669","article-title":"Second-Line treatment of HER2-positive salivary gland tumor: Ado-Trastuzumab emtansine (T-DM1) after progression on trastuzumab","volume":"11","author":"Corr\u00eaa","year":"2018","journal-title":"Case Rep Oncol"},{"key":"2025082802595984000_15.5.e248576.4","unstructured":"Cohen MJ . T-DM1: proof HER2 is a target in salivary gland cancers. Proceedings of UCLA Healthcare 2017;21."},{"key":"2025082802595984000_15.5.e248576.5","article-title":"Targeting HER2\/neu oncogene overexpression with Ado-Trastuzumab emtansine in the treatment of metastatic salivary gland neoplasms: a single-institution experience","volume":"3","author":"Swed","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"2025082802595984000_15.5.e248576.6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025082802595984000_15.5.e248576.7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s12254-020-00614-z","article-title":"Systemic therapy for metastatic salivary gland tumors\u2014challenges and novel concepts","volume":"13","author":"Minichsdorfer","year":"2020","journal-title":"Memo"},{"key":"2025082802595984000_15.5.e248576.8","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1634\/theoncologist.2019-0841","article-title":"The benefits of adjuvant trastuzumab for HER-2-positive salivary gland cancers","volume":"25","author":"Hanna","year":"2020","journal-title":"Oncologist"},{"key":"2025082802595984000_15.5.e248576.9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693394","article-title":"Her2 positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis","volume":"11","author":"Egebjerg","year":"2021","journal-title":"Front Oncol"},{"key":"2025082802595984000_15.5.e248576.10","doi-asserted-by":"crossref","first-page":"e760","DOI":"10.1097\/CAD.0000000000001181","article-title":"Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma","volume":"33","author":"Taha","year":"2022","journal-title":"Anticancer Drugs"},{"key":"2025082802595984000_15.5.e248576.11","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025082802595984000_15.5.e248576.12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00274","article-title":"Trastuzumab emtansine for the treatment of HER-2 positive carcinoma Ex-pleomorphic adenoma metastatic to the brain: a case report","volume":"8","author":"Hassanieh","year":"2018","journal-title":"Front Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-248576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:00:09Z","timestamp":1756375209000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-248576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,31]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/bcr-2021-248576"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-248576","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}